Our Work

How we help

The Karen Ingram Foundation was founded in 2008 and set up in memory of Karen Jane Ingram, a mother of two from Portsmouth who sadly passed away from Non-Hodgkin Lymphoma in July of that year, age just 40.

We raise funds for the research and development in the blood cancer Non-Hodgkin Lymphoma.


Our Foundation is split in to two core areas of focus; Research and Awareness. We want to educate people about the disease whilst also raising funds to treat it.

Since 2020 we have provided over £10,000 in financial grants for medical researchers to undertake clinical cancer trials in to the disease.

We are passionate about making a difference to the lives of people affected by Non-Hodgkin Lymphoma and through our Foundation we hope to prevent one less family going through the same thing we have in losing Karen.


We provide grants to medical researchers who undertake clinical cancer trials to see which treatments are most effective at treating Non-Hodgkin Lymphoma.

Recently, we have been fortunate to work with the Southampton Centre For Cancer Immunology on a unique 'Immunotherapy' programme which looks to harness the power of the bodies' immune system to detect and ultimately destroy lymphoma cancer cells.

Professor Peter Johnson thanks supporters of The Karen Ingram Foundation



What is Non-Hodgkin Lymphoma?

Non-Hodgkin's Lymphoma is a cancer which affects the cells of the lymphatic system, known as white blood cells.


There are more than 60 different types of the disease, making it the fifth most common cancer in the UK.

In the UK alone, over 13,000 people are diagnosed with the disease each year with approximately 4,700 attributable deaths. The incidence rate of Non-Hodgkin's Lymphoma has increased by 160% over the last three decades.


Health experts predict it could be as common as lung or breast cancer by 2025 if cases continue to increase at the same rate.

By holding regular fundraising events and by having a presence within the wider community, we hope to shine a light on this terrible disease and bring it to the forefront of the public's consensus in the hope we can work together in the fight against it.